News & Updates
Filter by Specialty:
Hepatitis C reinfection rates up in direct-acting antiviral era
There is an increased rate of hepatitis C virus (HCV) reinfection among people who inject drugs after the scale-up of direct-acting antivirals, reports a recent Scotland study.
Hepatitis C reinfection rates up in direct-acting antiviral era
26 Feb 2022
STRIDE regimen boosts OS in unresectable HCC
The addition of tremelimumab to durvalumab (STRIDE regimen) in the first-line setting improved overall survival (OS) compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma (HCC), according to results of the phase III HIMALAYA trial.
STRIDE regimen boosts OS in unresectable HCC
25 Feb 2022
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
In individuals with advanced hepatocellular carcinoma (HCC), the combination of transarterial chemoembolization (TACE) and lenvatinib as first-line treatment led to improved survival outcomes as opposed to lenvatinib monotherapy, according to findings of the phase III LAUNCH* trial.
Lenvatinib-TACE combo a new first-line treatment alternative for advanced liver cancer?
23 Feb 2022
Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal
The chances of hepatitis B surface antigen (HBsAg) loss after withdrawing nucleo(s)tide analogue (NUC) treatment depend on factors such as patient ethnicity, end-of-treatment antigen levels, and HBV genotype, a new study reports.